Answer
Yes. Bleeding is its principal safety risk and may occur at the arterial access site or elsewhere; severe bleeding is uncommon but potentially life-threatening.
Sources for this answer
- Kengrexal 50 mg powder for concentrate for solution for injection / infusion.emc · SmPC Current selected SmPC · Version 8